RITUXIMAB FOR THE TREATMENT OF RHEUMATIOD ARTHRITIS PATIENTS WITH FAILURE TO THE FIRST BIOLOGIC DRUG: IMPACT ON REPUBLIC FUND FOR HEALTH INSURANCE IN SERBIA
Abstract
Considering high prices of biologic drugs, using a cost-effective option for treatment of patients with rheumatoid arthritis who did not respond well to first biologic drug would have highly beneficial impact on health insurance budget. The aim of this study was to explore impact on budget of Republic Fund for Health Insurance (RFHI) caused by replacing etanercept with rituximab for treatment of rheumatoid arthritis patients who failed to respond to the first-line biologic drug. A Markov model with 5 states was constructed, having eight 6-months cycles. The perspective of the RFHI was used in the model, and annual savings in Serbia caused by using rituximab instead of etanercept were calculated.
Using rituximab instead of etanercept for treatment of 20% of rheumatoid arthritis patients who failed to respond to the first-line biologic drug in would lead to absolute annual savings of 144,115,218.09 ± 431,906,009.46 RSD. The annual drug budget of RFHI would be decreased for 0.24 ± 0.73 %, while total annual budget of RFHI would drop for 0.07 ± 0.21 % .
Based on the results of our study, using rituximab instead of etanercept for treatment of rheumatoid arthritis patients who failed to respond to the first-line biologic drug is a cost-effective option in Serbia, which would bring significant savings to RFHI.References
Neovius M, Simard JF, Askling J; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011; 70(4): 624-9.
Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 2012 Mar 27. [Epub ahead of print].
Fernández-Nebro A, Irigoyen MВ, Ureña I, Belmonte-López MA, Coret В, Jiménez-Núñez FG, Díaz-Cordo-vés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P. Effectiveness, predi-ctive response factors, and safety of anti-tumor necro-sis factor (TNF) therapies in anti-TNF-naive rheuma-toid arthritis. J Rheumatol 2007; 34(12): 2334-42.
Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012; 91(1): 30-43.
Soini EJ, Hallinen TA, Puolakka K, Вihervaara В, Kauppi MJ. Cost-effectiveness of adalimumab, etane-rcept, and tocilizumab as first-line treatments for mo-derate-to-severe rheumatoid arthritis. J Med Econ 2012; 15(2): 340-51.
Правилник о Листи лекова који се прописују и издају на терет средстава обавезног здрaвственог осигурања. Службени гласник РС бр. 1/2012.
Тарифна књига РФЗО-а, август 2012.
База података Финансијске службе Клиничког цен-тра Крагујевац, 10.8.2012.
Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, França LR, Boissier MC. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75(6): 688-95.
Одлука о изменама и допунама финансијског плана Републичког фонда за здравствено осигурање за 2012. годину. Републички фонд за здравствено осигурање. Београд, новембар 2011. Доступно на: http://www.rzzo.gov.rs/download/finplan2012.pdf , последњи пут посећено 15.12.2012.
РЕУМАТОИДНИ АРТРИТИС, Национални водич за лекаре у примарној здравственој заштити, Репу-бличка стручна комисија за израду и имплемен-тацију водича у клиничкој пракси, Министарство здравља Републике Србије Издавач: Српско лекар-ско друштво - СЛД, 2005.
Mabthera. Sažetak karakteristika leka, Electronic Me-dicins Compendium, Roche Products Limited, dostup-no na: http://www.medicines.org.uk/EMC/medicine/2570/SPC/Mabthera, poslednji put posećeno 11.11.2012.
Etarnecept. Sažetak karakteristika leka, Electronic Me-dicnes Compendium, dostup-no na: http://www.medicines.org.uk/EMC/medicine/19162/SPC/Enbrel+50mg+solution+for+injection+in+pre-filled+syringe/, poslednji put posećeno 9.12.2012.
Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arth-ritis: a retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commer-cial managed-care plans in the 2 years following therapy initiation. J Med Econ 2012; 15(4): 635-43.
Infliximab. Sažetak karakteristika leka, Electronic Me-dicines Compendium, dostup-no na: http://www.medicines.org.uk/EMC/medicine/2570/SPC/Infliximab, poslednji put posećeno 11.11.2012.
Humira pre-filled pen (adalimumab). Sažetak karakte-ristika leka, Electronic Medicines Compendium, AbbВie Limited, dostupno na: http://www.medicines.org.uk/EMC/medicine/21201/SPC/Humira+Pre-filled+Pen%2c+Pre-filled+Syringe+and+Вial/ , poslednji put posećeno 14.1.2013.
Simponi 50 solution for injection (golimumab). Sažetak karakteristika leka, Electronic Medicines Compen-dium, Merck, Sharp & Dohme Limited, dostupno na: http://www.medicines.org.uk/emc/medicine/23766#PHARMACOLOGICAL_PROPS , poslednji put posećeno 14.1.2013.
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10(42): 1-229.
Saraux A, Gossec L, Goupille P, Bregman B, Boccard E, Dupont D, Beresniak A. Cost-effectiveness mode-lling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 2010; 49(4): 733-40.
Benucci M, Iannazzo S, Zaniolo O, Sabadini L. Ritu-ximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol 2010; 28(5): 722-7.
Pravilnik о kriterijumima, načinu i postupku za stav-ljanje, odnosno skidanje lekova sa liste lekova koji se propisuju i izdaju na teret sredstava obaveznog zdrav-stvenog osiguranja. Službeni glasnik RS, br. 24/12 od 30.03.2012.